Comparison of in vivo efficacy of BCX-1777 and cyclosporin in xenogeneic graft-vs.-host disease: the role of dGTP in antiproliferative action of BCX-1777

This publication has 17 references indexed in Scilit:

• Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)—a novel potent and orally active immunosuppressive agent
  International Immunopharmacology, 2001
• Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes
  Proceedings of the National Academy of Sciences, 2001
• Effects of a novel purine nucleoside phosphorylase inhibitor, BCX-34, on activation and proliferation of normal human lymphoid cells
  Immunopharmacology, 1998
• One-Third-the-Sites Transition-State Inhibitors for Purine Nucleoside Phosphorylase
  Biochemistry, 1998
• In vivo and in vitro pharmacologic activity of the purine nucleoside phosphorylase inhibitor BCX-34: the role of GTP and dGTP
  Immunopharmacology, 1996
• A HUMAN MODEL OF XENOGENEIC GRAFT-VERSUS-HOST DISEASE IN SCID MICE ENGRAFTED WITH HUMAN PERIPHERAL BLOOD LYMPHOCYTES
  Transplantation, 1995
• Enzymatic assay for deoxyribonucleoside triphosphates using synthetic oligonucleotides as template primers
  Analytical Biochemistry, 1989
• Abnormal Purine Metabolism and Purine Overproduction in a Patient Deficient in Purine Nucleoside Phosphorylase
  New England Journal of Medicine, 1976
• An abnormal form of purine nucleoside phosphorylase in a family with a child with severe defective T-cell-and normal B-cell immunity
  Clinica Chimica Acta; International Journal of Clinical Chemistry, 1976
• NUCLEOSIDE-PHOSPHORYLASE DEFICIENCY IN A CHILD WITH SEVERELY DEFECTIVE T-CELL IMMUNITY AND NORMAL B-CELL IMMUNITY
  The Lancet, 1975